Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
DXP2GT
|
||||
| Drug Name |
N-(1-((cyanomethyl)carbamoyl)cyclohexyl)-4-morpholinobenzamide
|
||||
| Synonyms |
CHEMBL200301
|
||||
| Indication | Discovery agent | Investigative | [1587926] | ||
| Formula |
C20H26N4O3
|
||||
| Canonical SMILES |
O=C(NC1(CCCCC1)C(=O)NCC#N)c2ccc(cc2)N3CCOCC3
|
||||
| InChI |
InChI=1S/C20H26N4O3/c21-10-11-22-19(26)20(8-2-1-3-9-20)23-18(25)16-4-6-17(7-5-16)24-12-14-27-15-13-24/h4-7H,1-3,8-9,11-15H2,(H,22,26)(H,23,25)
|
||||
| InChIKey |
VPDSKJMUTGIXQJ-UHFFFAOYSA-N
|
||||
| Target and Pathway | |||||
| Target(s) | Cathepsin K | Target Info | [1587926] | ||
| Cathepsin B | Target Info | [1587926] | |||
| Reactome | Collagen degradation | ||||
| Degradation of the extracellular matrix | |||||
| Activation of Matrix Metalloproteinases | |||||
| Trafficking and processing of endosomal TLR | |||||
| MHC class II antigen presentationR-HSA-1442490:Collagen degradation | |||||
| Assembly of collagen fibrils and other multimeric structures | |||||
| MHC class II antigen presentation | |||||
| WikiPathways | RANKL/RANK Signaling Pathway | ||||
| Osteoclast Signaling | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.